5Picken MM. New insights into systemic amyloidosis:the importance of diagnosis of specific type [ J]. Curr Opin Nephrol Hypertens, 2007,16 : 196 - 203.
二级参考文献13
1Rocken C, Sletten K. Amyloid in surgical pathology. Virchows Arch,2003, 443: 3-16.
2Black RM. Amyloidosis and light-chain deposition disease. In: Black RM,ed. Clinical problems in nephrology. Boston: Little, Brown,1996. 305-314.
3Park MA, Mueller PS, Kyle RA, et al. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients.Medicine, 2003, 82: 291-298.
4Goeminne A, Missault L, Bauwens F, et al. Clinical experience with cardiac amyloidosis. Acta Cardiol, 2003, 58: 143-147.
5Guy CD, Jones Ck. Abdominal fat pad aspiration biopsy for tissue confirmation of systemic amyloidosis: specificity, positive predictive value, and diagnostic pitfalls. Diagn Cytopathol, 2001,24:181-185.
7Jacobson JL,Hussein MA,Barlogie B,et al.A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG)experience.Br J Haematol,2003,122(3):441-450
8Lauta VM.A review of the cytokine network in multiple myeloma:diagnostic,prognostic and therapeutic implications.Cancer,2003,97(10):2440-2452
9Solary E,Guiguet M,Zeller V,et al,Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma.Am J Hematol,1992,39(3):163-171
10Scudla V,Bacovsky J,Budikova M,et al,Serum interleukin-6 in multiple myeloma:I.Relation to selected laboratory indicators of disease.Vnitr Lek,1995,41(9):593-598
